Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential  Treatment for Duchenne Muscular Dystrophy  

TORONTO, March 9, 2023 – Satellos Bioscience Inc. (TSXV: MSCL | OTCQB: MSCLF) (“Satellos” or the  Company“), a drug discovery company developing small molecule therapeutics to regenerate muscle as  a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce  additional results from further preclinical studies using the Company’s lead drug candidate SAT-3153.  

The Company has designed SAT-3153 to be a selective inhibitor of a protein kinase (code named “K9”)  which it identified as a potential drug target to modulate polarity in muscle stem cells. On January 3, 2023,  the Company indicated that results from preclinical ADME, PK and in vivo studies led to designation of  SAT-3153 as its lead pre-IND drug development candidate (“DC”) for the treatment of Duchenne muscular  dystrophy (“Duchenne”). In a subsequent study with SAT-3153, in an acute injury model intended to  determine if drug is acting rapidly on mechanism, Mdx mice treated with SAT-3153 displayed a statistically  significant effect on polarity through new progenitor muscle cell formation vs placebo controls (n=5 per  group), after one (1) week. In a further in vivo study, Mdx mice treated with SAT-3153 four times per week  vs placebo controls (n=8 per group) showed a 19% increase in muscle force after two weeks. Additional  preclinical studies have shown SAT-3153 to have no binding of the hERG channel (a key requirement to  rule out possible cardiac toxicity), a plasma protein binding level of < 90% (indicating significant levels of  free drug are available to initiate a therapeutic effect), and oral bioavailability.  

“We see these results as a positive indication that SAT-3153 is on mechanism, affects skeletal muscle  regeneration as intended, and has the potential to be safe on critical drug development criteria,” said  Frank Gleeson, President and CEO of Satellos. “As preliminary, fact-finding studies which were designed  to contribute to the profile of SAT-3153 as a DC and establish early efficacy benchmarks to guide further  development studies, we are very pleased with these outcomes”. 

Commented Dr. Michael Rudnicki, the Company’s co-founder and Chief Scientific Officer, “It is so  gratifying to see that we have our own, proprietary drug with the potential to reset the body’s innate  regenerative ability in skeletal muscle. It has been our dream to develop a small molecule that could help  people living with Duchenne regardless of their exon mutation status, level of background AAV antibodies  or ambulatory status. We are one step closer to making that dream a reality”. 

Dr. Phil Lambert, Chief Technical Officer with overall responsibility for drug development at Satellos,  added, “These results build further confidence in SAT-3153’s potential as a treatment for Duchenne and  other muscle disorders. We will now focus on the next steps in the process, including to establish the  preferred oral dosing paradigm to optimize the drug’s beneficial effects on skeletal muscle which we  believe have the potential to be cumulative and sustainable over time. In parallel, we have initiated and  will continue to drive the prescribed pre-IND studies required to be included in an IND submission prior  to initiating human clinical trials.”  

Satellos asserts that a dysfunction in the normal process of stem cell polarity in response to muscle  damage represents a previously unrecognized root cause of Duchenne. The goal of correcting polarity in  Duchenne is to restore the body’s innate ability to regenerate muscle in response to the ongoing damage 

experienced by people living with Duchenne. SAT-3153 has been designated by Satellos as its lead drug  candidate and the Company is pursuing pre-IND development activities.  

About Satellos Bioscience Inc. 

Satellos is a biotechnology company dedicated to developing life-changing medicines to treat  degenerative muscle conditions. Our scientists discovered what we believe to be a previously  unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how  muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who  discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He  has shown how defects in a process known as stem cell “polarity”, which controls how muscle stem cells  divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and  potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of  new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the  continuous and accumulating damage their muscles experience. Satellos’ lead program is focused on  developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore  the body’s innate muscle repair and regeneration process. We believe our unique therapeutic approach  represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new  hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos  has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations  where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic  treatment. For more information about or to discuss potential collaborations with Satellos concerning our  discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please  contact Ryan Mitchell, Ph.D., Director – Business Development at [email protected] or visit 


Communications at Satellos Bioscience Inc. 

Christina Cameron 

[email protected] 


Notice on forward-looking statements: 

This press release includes forward-looking information or forward-looking statements within the  meaning of applicable securities laws regarding Satellos and its business, which may include, but are not  limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for  Duchenne; the general benefits of modulating stem cell polarity by administering small molecule drugs;  its/their prospective impact on Duchenne patients and muscle regeneration generally; the utility of  regenerating muscle by modulating polarity; adoption of Satellos’ approach by the medical community;  and Satellos’ technologies and drug development plans. All statements that are, or information which is,  not historical facts, including without limitation, statements regarding future estimates, plans, programs,  forecasts, projections, objectives, assumptions, expectations or beliefs of future performance,  occurrences or developments, are “forward-looking information or statements”. Often but not always, 

forward-looking information or statements can be identified by the use of words such as “shall”, “intends”,  “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” ,  “assert” or any variations (including negative or plural variations) of such words and phrases, or state that  certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead  to, result in, or, be achieved. Such statements are based on the current expectations and views of future  events of the management of the Company. They are based on assumptions and subject to risks and  uncertainties. Although management believes that the assumptions underlying these statements are  reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in  this release, may not occur and could differ materially as a result of known and unknown risk factors and  uncertainties affecting the Company, including risks relating to the pharmaceutical and bioscience  industry, general market conditions and equity markets, economic factors and management’s ability to  manage and to operate the business of the Company generally. Although Satellos has attempted to  identify important factors that could cause actual actions, events or results to differ materially from those  described in forward-looking statements, there may be other factors that cause actions, events or results  to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue  reliance on any forward-looking statements or information. No forward-looking statement can be  guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of  the date on which they are made and Satellos does not undertake any obligation to publicly update or  revise any forward-looking statement, whether as a result of new information, future events, or  otherwise. 

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX  Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX  Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.